Thyroid treatment

Graves' Orbitopathy: A Multidisciplinary Approach - Questions and Answers

Volumn , Issue , 2010, Pages 100-110

  Marcocci, Claudio ^a   Pinchera, Aldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952294452     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000320433     Document Type: Chapter

References (40)

1. Bartalena L, Pinchera A, Marcocci C: Management of Graveś ophthalmopathy: reality and perspectives . Endocr Rev 2000;21:168-199.
2. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A: Studies on the occurrence of ophthalmopathy in Graveś disease. Acta Endocrinol (Copenh) 1989;120:473-478.
3. Marcocci C, Bartalena L, Bogazzi F, BrunoBossio G, Pinchera A: Relationship between Graveś ophthalmopathy and type of treatment of Graveś hyperthyroidism. Thyroid 1992;2:171-178.
4. Perros P, Crombie AL, KendallTaylor P: Natural history of thyroidassociated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42:45-50.
5. Solomon B, Glinoer D, Lagasse R, Wartofsky L: Current trends in the management of Graveś disease. J Clin Endocrinol Metab 1990;70:1518-1524.
6. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R: Amelioration of eye changes of Graveś ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 1989;121(suppl 2):185-189.
7. Bartalena L, Tanda ML, Piantanida E, Lai A, Pinchera A: Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 2004;27:288-294.
8. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A: Clinical features of patients with Graveś disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369-375.
9. Marcocci C, Bartalena L, Pinchera A: Ablative or nonablative therapy for Graveś hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998;21:468-471.
10. Pinchera A, Bartalena L, Marcocci C: Radioiodine may be bad for Graveś ophthalmopathy, but.... J Clin Endocrinol Metab 1995;80:342-345.
11. Bonnema SJ, Bartalena L, Toft AD, Hegedüs L: Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and the use in large goiters. Eur J Endocrinol 2002;147:1-11.
12. Gorman CA: Radioiodine therapy does not aggravate Graveś ophthalmopathy. J Clin Endocrinol Metab 1995;80:340-342.
13. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A: Use of corticosteroids to prevent progression of Graveś ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349-1352.
14. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A, the Thyroid Study Group: Occurrence of ophthalmopathy after treatment for Graveś hyperthyroidism. N Engl J Med 1992;326:1733-1738.
15. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, BrunoBossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A: Relation between therapy for hyperthyroidism and the course of Graveś ophthalmopathy. N Engl J Med 1998;338:73-78.
16. Träisk F, Tallstedt L, AbrahamNordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT 96: Thyroidassociated ophthalmopathy after treatment for Graveś hyperthyroidism with antithyroid drugs or iodine131. J Clin Endocrinol Metab 2009;94:3700-3707.
17. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P: Radioiodine therapy (RAI) for Graveś disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008;69: 943-950.
18. Perros P, KendallTaylor P, Neoh C, Frewin S, Dickinson J: A prospective study on the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graveś ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321-5323.
19. Bartalena L: Editorial: Glucocorticoids for Graveś ophthalmopathy: how and when. J Clin Endocrinol Metab 2005;90:5497-5499.
20. Vannucchi G, Campi I, Covelli D, Dazzi D, Currò N, Simonetta S, Ratiglia R, BeckPeccoz P, Salvi M: Graveś orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009;94:3381-3386.
21. Kung AWC, Yau CC, Cheng A: The incidence of ophthalmopathy after radioiodine therapy for Graveś disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 1994;79:542-546.
22. Teng WP, Stark R, Munro AJ, Young SM, Borysiewicz LK, Weetman AP: Peripheral blood T cell activation after radioiodine treatment for Graveś disease. Acta Endocrinol (Copenh) 1990;122:233-240.
23. DeGroot LJ: Radioiodine and the immune system. Thyroid 1997;7:259-264.
24. Marcocci C, BrunoBossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L: The course of Graveś ophthalmopathy is not influenced by neartotal thyroidectomy: a casecontrol study. Clin Endocrinol (Oxf) 1999;51:503-508.
25. Tanda ML, Lai A, Bartalena L: Relation between Graveś orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions. Clin Endocrinol (Oxf) 2008;69:845-847.
26. Wiersinga WM: Preventing Graveś ophthalmopathy. N Engl J Med 1998;338:121-122.
27. Karlsson Af, Westermark K, Dahlberg PA, Jansson R, Enoksson P: Ophthalmopathy and thyroid stimulation. Lancet 1989;ii:691.
28. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG: Thyrotropin receptor autoantibodies are independent risk factors for Graveś ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:3464-3470.
29. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A: Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998;129:632-635.
30. Tallstedt L, Lundell G, Blomgren H, Bring J: Does early administration of thyroxine reduce the development of Graveś ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494-497.
31. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L: Lower doses prednisone prevents radioiodineassociated exacerbation of initially mild or absent Graveś orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010;95:1333-1337.
32. Jensen BE, Bonnema SJ, Hegedüs I: Glucocorticoids do not influence the effect of radioiodine therapy in Graveś disease. Eur J Endocrinol 2005;153:15-21.
33. Weetman A, Wiersinga WM: Current management of thyroid associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 1988;49:21-28.
34. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A: Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-351.
35. Catz B, Perzik SL: Total thyroidectomy in the management of thyrotoxic and euthyroid Graveś disease. Am J Surg 1969;118:434-438.
36. Werner SC, Feind CR, Aida M: Graveś disease and total thyroidectomy. Progression of severe eye changes and decrease in serum longacting thyroid stimulator after operation. N Eng J Med 1967;276: 132-138.
37. De Groot LJ, Benjasuratwong Y: Evaluation of thyroid ablative therapy for ophthalmopathy of Graveś disease. Orbit 1996;15:187-196.
38. Moleti M, Mattina F, Salamone I, Violi MA, Numera C, Bardari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F: Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graveś ophthalmopathy. Thyroid 2003;13:653-658.
39. Järhult J, Rudberg C, Larsson E, Selvander H, Sjövall K, Winsa B, Rastad J, Karlsson FA, the TEO Study Group: Graveś disease with moderatesevere endocrine ophthalmopathy: long term results of a prospective randomized study of total or subtotal thyroid resection. Thyroid 2005;15:1157-1164.
40. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C: Effects of total thyroid ablation vs. total thyroidectomy alone on the short term outcome of mild to moderate Graveś orbitopathy treated with intravenous glucocorticoids. J Clin Endoc Metab 2007;92:1653-1658.